Table 1.
General characteristic of the study subjects.
| miRNA array cohort | P | validation cohor | P | |||
|---|---|---|---|---|---|---|
| CLI | Non - CLI | CLI | Non - CLI | |||
| No. of subjects | 4 | 4 | — | 27 | 31 | — |
| Age, y | 65.00 ± 1.73 | 65.50 ± 1.55 | 0.837 | 64.30 ± 2.73 | 61.0, (56.0–69.0) | 0.790‡ |
| T2D Duration, y | 10.00 ± 1.41 | 12.25 ± 1.80 | 0.363 | 15.48 ± 1.47 | 9.0, (8.0–14.0) | 0.004 ‡ |
| Women, % | 2, (50.00) | 2, (50.00) | 1.000 | 14, (51.85) | 16, (51.61) | 0.986† |
| Hyperlipidemia, % | 0, (0) | 2, (50.00) | 0.429 | 10, (37.04) | 10, (32.26) | 0.702† |
| Hypertension, % | 2, (50.00) | 2, (50.00) | 1.000 | 16, (59.26) | 9, (29.03) | 0.020 † |
| Smoking, % | 2, (50.00) | 2, (50.00) | 1.000 | 15, (55.56) | 8, (25.81) | 0.021 † |
| ABI | 0.46 ± 0.10 | 1.06 ± 0.03 | 0.007 | 24.10 (22.70–25.80) | 1.11 ± 0.01 | 0.000 ‡ |
| BMI, kg/m2 | 23.80 ± 1.21 | 25.98 ± 1.99 | 0.386 | 24.95 ± 0.57 | 25.46 ± 0.52 | 0.512 |
| CAD, % | 2, (50.00) | 2, (50.00) | 1.000 | 8, (29.63) | 8, (25.81) | 0.745† |
| Statin use, % | 0, (0) | 1, (25.00) | 1.000 | 6, (22.22) | 4, (12.90) | 0.349† |
| Antihypertensive treatment use, % | 2, (50.00) | 1, (25.00) | 1.000 | 8, (29.63) | 5, (16.13) | 0.219† |
| FPG, mmol/L | 8.27 ± 2.69 | 7.87 ± 1.52 | 0.899 | 9.60 (8.65–14.36) | 7.27 (6.14–9.05) | 0.001 ‡ |
| HbA1c, % | 10.35 ± 1.15 | 7.48 ± 0.31 | 0.509 | 8.90 (7.90–9.60) | 6.90 (6.50–9.00) | 0.001 ‡ |
| HDL-C, mmol/L | 0.97 ± 0.08 | 1.06 ± 0.06 | 0.372 | 1.08 ± 0.05 | 1.16 (0.90–1.32) | 0.281‡ |
| LDL-C, mmol/L | 2.14 ± 0.16 | 3.10 ± 0.41 | 0.100 | 2.63 ± 0.17 | 2.63 ± 0.15 | 0.987 |
| TG, mmol/L | 1.29 ± 0.33 | 1.37 ± 0.45 | 0.901 | 1.48 (1.07–1.86) | 1.29 (0.92–1.84) | 0.847‡ |
| TC, mmol/L | 3.51 ± 0.23 | 4.69 ± 0.42 | 0.048 | 2.80 (2.55–3.68) | 4.30 ± 0.18 | 0.006 ‡ |
| Apo A, g/L | 1.09 ± 0.07 | 1.19 ± 0.04 | 0.248 | 1.16 (1.03–1.29) | 1.15 (1.06–1.35) | 0.172‡ |
| Apo B, g/L | 0.80 ± 0.06 | 0.96 ± 0.10 | 0.194 | 0.92 ± 0.04 | 0.86 ± 0.04 | 0.265 |
| Cr, μmol/L | 55.50 ± 6.36 | 72.75 ± 9.58 | 0.184 | 75.00 (58.00–107.00) | 65.00 (55.00–72.00) | 0.044 ‡ |
| BUN, mmol/L | 4.95 ± 0.93 | 6.24 ± 1.06 | 0.393 | 5.60 (4.60–7.24) | 6.11 ± 0.40 | 0.374‡ |
| UA, mmol/L | 268.00 ± 10.96 | 262.25 ± 39.80 | 0.897 | 327.97 ± 13.45 | 323.76 ± 18.77 | 0.860 |
| Total bilirubin, mol/L | 11.63 ± 1.48 | 10.03 ± 1.71 | 0.586 | 12.51 ± 0.97 | 12.50 ± 0.87 | 0.995 |
| hsCRP, mg/dL | 1.24 ± 0.69 | 0.64 ± 0.25 | 0.446 | 0.35 (0.19–1.36) | 0.64 (0.26–2.30) | 0.402‡ |
| ALT, U/L | 18.00 ± 7.53 | 22.00 ± 5.02 | 0.674 | 14.60 (8.00–26.00) | 14.00 (10.90–23.00) | 0.343‡ |
| AST, U/L | 21.75 ± 3.78 | 22.50 ± 2.72 | 0.877 | 19.00 (13.00–31.00) | 19.28 ± 1.25 | 0.136‡ |
ABI, Ankle brachial index; BMI, body mass index; CAD, coronary artery disease; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; Apo A, Apolipoprotein A; Apo B, Apolipoprotein B; Cr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; hsCRP, high-sensitivity C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Data is expressed as mean ± SEM, median (interquartile range) or percentage. Significant values are marked in italic. Continuous variales were compared by the Fisher-Pitman Permutation test, and categorical variables were compared by Fisher’s exact test in the miRNA array cohort, however, the validation cohort was analyzed using †χ2 test or ‡Mann-Whitney U-test, and the others were analyzed using t-tests.